EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Neuronetics's enterprise value is $300.23 Mil.
Neuronetics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-39.54 Mil. Therefore, Neuronetics's EV-to-EBITDA for today is -7.59.
The historical rank and industry rank for Neuronetics's EV-to-EBITDA or its related term are showing as below:
STIM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -34.23 Med: -3.11 Max: 0.56
Current: -7.59
During the past 9 years, the highest EV-to-EBITDA of Neuronetics was 0.56. The lowest was -34.23. And the median was -3.11.
STIM's EV-to-EBITDA is ranked worse than 100% of 495
companies
in the Medical Devices & Instruments industry
Industry Median: 15.58
vs STIM: -7.59
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Neuronetics EV-to-EBITDA Historical Data
The historical data trend for Neuronetics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Neuronetics's EV-to-EBITDA
For the Medical Devices subindustry, Neuronetics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuronetics's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neuronetics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Neuronetics's EV-to-EBITDA falls into.
Neuronetics's current Enterprise Value is $300.23 Mil.
Neuronetics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuronetics (NAS:STIM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Neuronetics's PE Ratio (TTM) for today is calculated as:
Neuronetics's share price for today is $3.57.
Neuronetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Neuronetics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STIM has been successfully added to your 